Johnson & Johnson EBITDA 2006-2019 | JNJ

Johnson & Johnson annual and quarterly EBITDA history from 2006 to 2019. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Johnson & Johnson EBITDA for the quarter ending June 30, 2019 was $8.917B, a 26.14% increase year-over-year.
  • Johnson & Johnson EBITDA for the twelve months ending June 30, 2019 was $27.176B, a 3.48% increase year-over-year.
  • Johnson & Johnson 2018 annual EBITDA was $26.544B, a 7.75% increase from 2017.
  • Johnson & Johnson 2017 annual EBITDA was $24.634B, a 0.07% decline from 2016.
  • Johnson & Johnson 2016 annual EBITDA was $24.651B, a 4.36% increase from 2015.
Johnson & Johnson Annual EBITDA
(Millions of US $)
2018 $26,544
2017 $24,634
2016 $24,651
2015 $23,622
2014 $25,058
2013 $20,131
2012 $18,037
2011 $16,181
2010 $20,448
2009 $19,070
2008 $20,557
2007 $16,808
2006 $17,656
2005 $15,750
Johnson & Johnson Quarterly EBITDA
(Millions of US $)
Q2 2019 $8,917
Q1 2019 $6,384
Q4 2018 $5,303
Q3 2018 $6,572
Q2 2018 $7,069
Q1 2018 $7,600
Q4 2017 $4,788
Q3 2017 $6,804
Q2 2017 $6,230
Q1 2017 $6,812
Q4 2016 $5,663
Q3 2016 $6,478
Q2 2016 $6,082
Q1 2016 $6,428
Q4 2015 $5,004
Q3 2015 $5,206
Q2 2015 $6,785
Q1 2015 $6,627
Q4 2014 $3,850
Q3 2014 $7,897
Q2 2014 $6,720
Q1 2014 $6,591
Q4 2013 $4,004
Q3 2013 $4,766
Q2 2013 $5,918
Q1 2013 $5,443
Q4 2012 $4,261
Q3 2012 $4,750
Q2 2012 $3,044
Q1 2012 $5,982
Q4 2011 $1,379
Q3 2011 $5,045
Q2 2011 $4,346
Q1 2011 $5,411
Q4 2010 $3,159
Q3 2010 $5,065
Q2 2010 $5,075
Q1 2010 $7,149
Q4 2009 $3,453
Q3 2009 $5,090
Q2 2009 $5,077
Q1 2009 $5,450
Q4 2008 $4,435
Q3 2008 $5,277
Q2 2008 $5,252
Q1 2008 $5,593
Q4 2007 $3,428
Q3 2007 $4,081
Q2 2007 $4,868
Q1 2007 $4,431
Q4 2006 $3,516
Q3 2006 $4,420
Q2 2006 $4,371
Q1 2006 $5,349
Q4 2005 $3,183
Q3 2005 $4,088
Q2 2005 $3,938
Q1 2005 $4,541
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $343.382B $81.581B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $244.080B 0.00
Merck (MRK) United States $214.995B 17.68
Pfizer (PFE) United States $201.939B 11.89
Novartis AG (NVS) Switzerland $197.897B 17.03
Novo Nordisk (NVO) Denmark $122.852B 21.71
AstraZeneca (AZN) United Kingdom $117.046B 22.65
Sanofi (SNY) France $112.486B 13.82
Eli Lilly (LLY) United States $110.397B 20.60
AbbVie (ABBV) United States $105.963B 8.49
GlaxoSmithKline (GSK) United Kingdom $103.061B 12.95
Bristol-Myers Squibb (BMY) United States $81.903B 11.62
Bayer (BAYRY) Germany $68.710B 10.01
H Lundbeck (HLUYY) Denmark $6.906B 9.97